XOMA acquires ebopiprant from ObsEva for $15M cash plus milestone earn-outs

XOMA Royalty Corp

XOMA pays $15M cash at closing to ObsEva for ebopiprant; assumes IP estate and all license agreements including Organon sublicense.
XOMA eligible for up to $475M in development, regulatory, and sales milestones from Organon; will pay ObsEva up to $98M of those.
Upon commercialization, XOMA receives low- to mid-teen royalties from Organon and pays mid-single-digit royalty to Merck KGaA.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

XOMA Royalty Corp entered into Intellectual Property Acquisition Agreement with ObsEva SA valued at $15 million upfront plus up to $98 million in milestone payments (effective 2022-11-21).

Action: entry
Agreement: asset purchase
Counterparty: ObsEva SA
Value: $15 million upfront plus up to $98 million in milestone payments
Effective: 2022-11-21

Exact text from the filing

On November 21, 2022, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an intellectual property acquisition agreement (the “Agreement”) with ObsEva, SA, a Swiss biotech company (“ObsEva”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-22-290445

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.